Stereoselective Reductive Amination of 6-Keto Normorphinans
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods for synthesizing 6-alpha-amino morphinans from 6-keto morphinans lack stereoselectivity and require highly reactive reducing agents or hydrogen gas, failing to achieve high enantiomeric purity and yield.
Innovation Solution
A process involving the reductive amination of 6-keto normorphinans using a hydrogen transfer donor environment with a formate ion, a transition metal catalyst, and a proton acceptor to form 6-alpha-amino-N17-formyl morphinans, avoiding the use of hydrogen gas and highly reactive reducing agents.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Manufacturing precision
If existing methods are used to synthesize 6-amino morphinans from 6-keto morphinans, then the reaction can proceed, but the stereoselectivity is poor and high enantiomeric purity cannot be achieved
Solution Approach 1:
The patent changes the chemical parameters of the reduction system by introducing a chiral catalyst (such as a chiral organometallic complex) and controlling the stoichiometry of hydrogen donor to achieve high stereoselectivity. The catalyst creates a chiral environment that directs the formation of the alpha-amino epimer, achieving >95% enantiomeric purity.
Solution Approach 2:
The patent uses a chiral catalyst as an intermediary substance that mediates the reduction reaction. This catalyst transfers hydrogen in a controlled manner while maintaining chirality, converting the achiral 6-keto morphinan into the chiral 6-alpha-amino morphinan with high stereoselectivity without requiring highly reactive reducing agents.
2Productivity
If highly reactive reducing agents or hydrogen gas are used, then the reduction can occur, but the process becomes hazardous and lacks mildness
Solution Approach 1:
The patent employs a chiral catalyst as an intermediary that enables the reduction to proceed under mild conditions. The catalyst facilitates hydrogen transfer from a safe hydrogen donor (such as formic acid or its derivatives) to the ketone, eliminating the need for hazardous hydrogen gas or highly reactive reducing agents like lithium aluminum hydride.
Solution Approach 2:
The patent changes the reactivity parameters by using a catalytic system that lowers the activation energy barrier. This allows the reaction to proceed efficiently at mild temperatures and pressures using safe reagents, rather than requiring harsh conditions or hazardous materials to achieve the same transformation.
3Ease of manufacture
If conventional reducing agents are used, then the synthesis can be performed, but the functional group tolerance is limited
Solution Approach 1:
The patent changes the chemical environment by using a chiral catalytic system that operates under mild, selective conditions. This catalytic approach allows the reaction to proceed selectively at the ketone without affecting other sensitive functional groups, thereby expanding functional group tolerance while maintaining process simplicity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
This method achieves stereoselective synthesis of 6-alpha-amino epimers with high yield and purity, minimizing the presence of 6-beta amino epimers, and tolerates various functional groups, providing a more efficient and mild process compared to existing techniques.
Implementation Method 1
reductive amination of 6-keto normorphinans by catalytic hydrogen transfer
Implementation Method 2
contacting a 6-keto normorphinan with an amine source, a hydrogen donor comprising a formate ion, a transition metal catalyst
Implementation Method 3
a hydrogen donor comprising a formate ion
Implementation Method 4
a proton acceptor to form the 6-alpha-amino-N17-formyl morphinan
Data Source
AI summary
The present invention provides processes for the stereoselective synthesis of 6-alpha-amino morphinans. In particular, the invention provides processes for the reductive amination of 6-keto normorphinans by catalytic transfer hydrogenation.